相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies
Chen Wang et al.
CURRENT OPINION IN HEMATOLOGY (2022)
Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint
Zhen-Hua Wu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
Leonie M. Behrens et al.
CANCERS (2022)
ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer
Rodney Cheng-En Hsieh et al.
SCIENCE IMMUNOLOGY (2022)
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2021)
Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Paolo Strati et al.
BLOOD (2021)
Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells
Gabriela Andrejeva et al.
JOURNAL OF IMMUNOLOGY (2021)
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
Nehal J. Lakhani et al.
LANCET ONCOLOGY (2021)
SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation
Safa Dehmani et al.
FRONTIERS IN IMMUNOLOGY (2021)
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sezary syndrome: a multicentre, phase 1 study
Christiane Querfeld et al.
LANCET HAEMATOLOGY (2021)
Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis
Roarke A. Kamber et al.
NATURE (2021)
Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy
Zhen Bian et al.
NATURE COMMUNICATIONS (2021)
Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy
Jie Liu et al.
JCI INSIGHT (2020)
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance
Vanessa Gauttier et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity
Darienne R. Myers et al.
FRONTIERS IN IMMUNOLOGY (2020)
Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
Tracy C. Kuo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα
Janet Sim et al.
MABS (2019)
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint
Erik Voets et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils
Louise W. Treffers et al.
FRONTIERS IN IMMUNOLOGY (2019)
Anti-human SIRP antibody is a new tool for cancer immunotherapy
Yoji Murata et al.
CANCER SCIENCE (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Hanke L. Matlung et al.
CELL REPORTS (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova et al.
CLINICAL CANCER RESEARCH (2017)
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
Meng Michelle Xu et al.
IMMUNITY (2017)
The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
Hanke L. Matlung et al.
IMMUNOLOGICAL REVIEWS (2017)
Shp1 function in myeloid cells
Clare L. Abram et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
Jun Chen et al.
NATURE (2017)
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity
Nan Guo Ring et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Exclusive transmission of the embryonic stem cell-derived genome through the mouse germline
Frank Koentgen et al.
GENESIS (2016)
Durable antitumor responses to CD47 blockade require adaptive immune stimulation
Jonathan T. Sockolosky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
David J. DiLillo et al.
CELL (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Jie Liu et al.
PLOS ONE (2015)
The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
A. Neil Barclay et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
Complement in Antibody-Based Tumor Therapy
Stefanie Derer et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2014)
Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47*
Deborah Hatherley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Nuray Gul et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Neutrophils mediate antibody-induced antitumor effects in mice
Marcello Albanesi et al.
BLOOD (2013)
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47
David R. Soto-Pantoja et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Distinct Roles for Neutrophils and Dendritic Cells in Inflammation and Autoimmunity in motheaten Mice
Clare L. Abram et al.
IMMUNITY (2013)
Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
Maya K. Leabman et al.
MABS (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
P. Mark Hogarth et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction
Xi Wen Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47
Sukhbir Kaur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Endothelial CD47 interaction with SIRPγ is required for human T-cell transendothelial migration under shear flow conditions in vitro
Michael Stefanidakis et al.
BLOOD (2008)
Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47
Deborah Hatherley et al.
MOLECULAR CELL (2008)
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects
Scott E. Strome et al.
ONCOLOGIST (2007)
Signal regulatory proteins in the immune system
EM van Beek et al.
JOURNAL OF IMMUNOLOGY (2005)
Adhesion of human T cells to antigen-presenting cells through SIRPβ2-CD47 interaction costimulates T-cell proliferation
L Piccio et al.
BLOOD (2005)
Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family
G Brooke et al.
JOURNAL OF IMMUNOLOGY (2004)
Renaissance of cancer therapeutic antibodies
MJ Glennie et al.
DRUG DISCOVERY TODAY (2003)
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
M Hezareh et al.
JOURNAL OF VIROLOGY (2001)
Signal-regulatory protein α (SIRPα) but not SIRPβ is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38- hematopoietic cells
M Seiffert et al.
BLOOD (2001)
Integrin-associated protein (CD47) and its ligands
EJ Brown et al.
TRENDS IN CELL BIOLOGY (2001)
Role of CD47 as a marker of self on red blood cells
PA Oldenborg et al.
SCIENCE (2000)
分享论文
